Biogen and Eisai change agreements on Alzheimer's drug
An amendment to Biogen and Eisai’s partnership deal means the latter will start receiving royalties from Aduhelm sales next year. The companies have also decided to extend collaborations on a new Alzheimer’s treatment.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
Going forward, Biogen and Eisai won’t be splitting global profits of Alzheimer’s drug Aduhelm (aducanumab), which is marketed in the US under the brand name Aduhelm, the companies announce in separate press releases.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen's Alzheimer's drug loses subsidies in the US
For subscribers
Biogen's Alzheimer's drug blocked in Japan
For subscribers
Biogen slashes price of controversial Alzheimer's drug
For subscribers
